GPCRs (G-Protein–Coupled Receptors) as Microprocessors

Abstract

Footnotes The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. For Disclosures, see page 434. Correspondence to: Kate M. Denton, Cardiovascular Disease Program, Monash Biomedicine Discovery Institute, Monash University, Wellington Rd, Clayton,, Victoria 3800, Australia. Email kate. [email protected] edu References 1. Eguchi S, Kawai T, Scalia R, Rizzo V. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. Hypertension . 2018; 71:804–810. doi: 10.1161/HYPERTENSIONAHA.118.10266 Link Google Scholar 2. Boutin JA, Legros C. The five dimensions of receptor pharmacology exemplified by melatonin receptors: an opinion. Pharmacol Res Perspect . 2020; 8:e00556. doi: 10.1002/prp2.556 Crossref Medline Google Scholar 3. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther . 2010; 335:572–579. doi: 10.1124/jpet.110.173005 Crossref Medline Google Scholar 4. Quarti Trevano F, Seravalle G, Macchiarulo M, Villa P, Valena C, Dell'Oro R, Mancia G, Grassi G. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. J Hypertens . 2017; 35:1685–1690. doi: 10.1097/HJH.0000000000001370 Crossref -Abstract Truncated-